Anticoagulants Market Share & Size Statistics Report – 2032

Anticoagulants Market - By Drug Class (Factor Xa Inhibitors, Heparin), Route of Administration (Oral, Injectables), Application (Thromboembolism, Atrial Fibrillation, Coronary Artery Disease), Distribution Channel & Global Forecast, 2023 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market definition

1.2&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3&nbsp;&nbsp;&nbsp; Forecast parameters

1.4&nbsp;&nbsp;&nbsp; COVID-19 impact analysis at global level

1.5&nbsp;&nbsp;&nbsp; Data validation

1.6&nbsp;&nbsp;&nbsp; Data Sources

1.6.1&nbsp;&nbsp;&nbsp; Primary

1.6.2&nbsp;&nbsp;&nbsp; Secondary

1.6.2.1&nbsp;&nbsp;&nbsp;Paid sources

1.6.2.2&nbsp;&nbsp;&nbsp;Public sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Anticoagulants industry 360&ordm; synopsis, 2018 &ndash; 2032

2.1.1&nbsp;&nbsp;&nbsp; Business trends

2.1.2&nbsp;&nbsp;&nbsp; Regional trends

2.1.3&nbsp;&nbsp;&nbsp; Drug category trends

2.1.4&nbsp;&nbsp;&nbsp; Route of administration trends

2.1.5&nbsp;&nbsp;&nbsp; Application trends

2.1.6&nbsp;&nbsp;&nbsp; Distribution channel trends

Chapter 3&nbsp;&nbsp;&nbsp;Anticoagulants Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp;Growing prevalence of chronic disease

3.2.1.2&nbsp;&nbsp;&nbsp;Growing adoption of novel oral anticoagulants (NOACs)

3.2.1.3&nbsp;&nbsp;&nbsp;Rising geriatric population across the globe

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp;High risk of side effects

3.2.2.2&nbsp;&nbsp;&nbsp;Stringent regulatory framework

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By drug category

3.3.2&nbsp;&nbsp;&nbsp; By route of administration

3.3.3&nbsp;&nbsp;&nbsp; By application

3.3.4&nbsp;&nbsp;&nbsp; By distribution channel

3.4&nbsp;&nbsp;&nbsp; COVID- 19 impact analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis, 2022

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Anticoagulants Market Size and Forecast, By Drug Category (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends, by drug category

5.2&nbsp;&nbsp;&nbsp; Factor Xa inhibitor

5.3&nbsp;&nbsp;&nbsp; Heparin

5.4&nbsp;&nbsp;&nbsp; Warfarin

5.5&nbsp;&nbsp;&nbsp; Direct thrombin inhibitor

5.6&nbsp;&nbsp;&nbsp; Others

Chapter 6&nbsp;&nbsp;&nbsp;Anticoagulants Market Size and Forecast, By Route of Administration (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends, by route of administration

6.2&nbsp;&nbsp;&nbsp; Oral

6.3&nbsp;&nbsp;&nbsp; Injectable

Chapter 7&nbsp;&nbsp;&nbsp;Anticoagulants Market Size and Forecast, By Application (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends, by application

7.2&nbsp;&nbsp;&nbsp; Venous thromboembolism

7.3&nbsp;&nbsp;&nbsp; Atrial fibrillation/flutter

7.4&nbsp;&nbsp;&nbsp; Coronary artery disease

7.5&nbsp;&nbsp;&nbsp; Others

Chapter 8&nbsp;&nbsp;&nbsp;Anticoagulants Market Size and Forecast, By Distribution Channel (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends, by distribution channel

8.2&nbsp;&nbsp;&nbsp; Hospital pharmacy

8.3&nbsp;&nbsp;&nbsp; Retail pharmacy

8.4&nbsp;&nbsp;&nbsp; Online pharmacy

Chapter 9&nbsp;&nbsp;&nbsp;Anticoagulants Market Size and Forecast, By Region (USD Million)

9.1&nbsp;&nbsp;&nbsp; Key trends, by region

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; Japan

9.4.2&nbsp;&nbsp;&nbsp; China

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.5.4&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

9.6.4&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Bristol-Myers Squibb Company

10.2&nbsp;&nbsp;&nbsp; Bayer AG

10.3&nbsp;&nbsp;&nbsp; Boehringer Ingelheim

10.4&nbsp;&nbsp;&nbsp; Johnson and Johnson

10.5&nbsp;&nbsp;&nbsp; Daiichi Sankyo Company

10.6&nbsp;&nbsp;&nbsp; Amphastar Pharmaceuticals, Inc.

10.7&nbsp;&nbsp;&nbsp; Leo pharma

10.8&nbsp;&nbsp;&nbsp; Pfizer

10.9&nbsp;&nbsp;&nbsp; ROVI

10.10&nbsp;&nbsp;&nbsp; Sanofi

10.11&nbsp;&nbsp;&nbsp; Shenzhen Hepalink

10.12&nbsp;&nbsp;&nbsp; United Therapeutics 
&nbsp;

Anticoagulants Market

Inquiry Before Buying

Industries

Information

Link

Global Headquarters